Selexis and TeneoBio Team Up to Advance the Development of UniAbs Targeting Cancer

Selexis SA and TeneoBio announced that they have entered into a service agreement to advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting cancer. Under the agreement, TeneoBio will leverage Selexis’ proprietary SUREtechnology Platform to develop and optimize the cellular expression of multi-specific UniAbs that were discovered using TeneoBio’s proprietary sequence-based TeneoSeek discovery engine and UniRat Human Heavy-Chain Antibody Platform.

“TeneoBio is developing a new class of multispecific biologics for treatments of multiple myeloma, lymphoma and prostate cancer,” said Yemi Onakunle, PhD, vice president, business development and licensing with Selexis. “We believe in the power of the Selexis SUREtechnology Platform to help TeneoBio to rapidly and predictably achieve the high antibody expression levels and cell line stability that are needed for the cost-effective production of their unique multi-specific antibody candidates.”

Selexis’ SUREtechnology platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including those that are difficult to express in other systems. It also provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization.

Omid Vafa, chief business officer at TeneoBio, Inc., added, “This is the first of several TeneoBio bi- and multi-specific UniAb candidates that leverages our unique T-cell redirection platform to target liquid and solid tumors. We are excited to work with Selexis, a pioneer in bioproduction that offers the right balance of speed, technology, and flexibility to generate cell lines for our lead program.”